Tags

Type your tag names separated by a space and hit enter

Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
Br J Ophthalmol. 2008 Nov; 92(11):1498-502.BJ

Abstract

OBJECTIVE

To evaluate open-angle glaucoma patients, who were insufficiently controlled on latanoprost monotherapy, to determine the 24 h intraocular pressure (IOP) efficacy and safety when changing them to dorzolamide/timolol (DTFC) or latanoprost/timolol fixed combination (LTFC) or adding DTFC.

METHODS

A prospective, observer-masked, placebo-controlled, crossover, comparison. Consecutive adults with primary open-angle or exfoliative glaucoma who exhibit a mean baseline IOP >21 mm Hg on latanoprost monotherapy were randomised for 3 months to: DTFC, LTFC or DTFC and latanoprost. Patients were then crossed over to the next treatment for periods 2 and 3. At the end of the latanoprost run-in and after each 3-month treatment period, patients underwent 24 h IOP monitoring.

RESULTS

31 patients completed this study. All three adjunctive therapies significantly reduced the IOP at each time point and for the mean 24 h curve, except at 18:00 and 02:00 with DTFC and 02:00 with LTFC. When the three treatments were compared directly, the DTFC and latanoprost therapy demonstrated lower IOPs versus the other treatment groups, including: the mean 24 h pressure, maximum as well as minimum levels and individual time points following a modified Bonferroni correction (p<0.0032).

CONCLUSIONS

This study showed DTFC, LTFC and the addition of DTFC to latanoprost significantly decrease the IOP compared with latanoprost alone, but the latter therapy regime yields the greatest IOP reduction.

Authors+Show Affiliations

Department Ophthalmology, Glaucoma Unit, 1st University, Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18703549

Citation

Konstas, A G P., et al. "Second-line Therapy With Dorzolamide/timolol or Latanoprost/timolol Fixed Combination Versus Adding Dorzolamide/timolol Fixed Combination to Latanoprost Monotherapy." The British Journal of Ophthalmology, vol. 92, no. 11, 2008, pp. 1498-502.
Konstas AG, Mikropoulos D, Dimopoulos AT, et al. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol. 2008;92(11):1498-502.
Konstas, A. G., Mikropoulos, D., Dimopoulos, A. T., Moumtzis, G., Nelson, L. A., & Stewart, W. C. (2008). Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. The British Journal of Ophthalmology, 92(11), 1498-502. https://doi.org/10.1136/bjo.2008.145219
Konstas AG, et al. Second-line Therapy With Dorzolamide/timolol or Latanoprost/timolol Fixed Combination Versus Adding Dorzolamide/timolol Fixed Combination to Latanoprost Monotherapy. Br J Ophthalmol. 2008;92(11):1498-502. PubMed PMID: 18703549.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. AU - Konstas,A G P, AU - Mikropoulos,D, AU - Dimopoulos,A T, AU - Moumtzis,G, AU - Nelson,L A, AU - Stewart,W C, Y1 - 2008/08/14/ PY - 2008/8/16/pubmed PY - 2008/12/17/medline PY - 2008/8/16/entrez SP - 1498 EP - 502 JF - The British journal of ophthalmology JO - Br J Ophthalmol VL - 92 IS - 11 N2 - OBJECTIVE: To evaluate open-angle glaucoma patients, who were insufficiently controlled on latanoprost monotherapy, to determine the 24 h intraocular pressure (IOP) efficacy and safety when changing them to dorzolamide/timolol (DTFC) or latanoprost/timolol fixed combination (LTFC) or adding DTFC. METHODS: A prospective, observer-masked, placebo-controlled, crossover, comparison. Consecutive adults with primary open-angle or exfoliative glaucoma who exhibit a mean baseline IOP >21 mm Hg on latanoprost monotherapy were randomised for 3 months to: DTFC, LTFC or DTFC and latanoprost. Patients were then crossed over to the next treatment for periods 2 and 3. At the end of the latanoprost run-in and after each 3-month treatment period, patients underwent 24 h IOP monitoring. RESULTS: 31 patients completed this study. All three adjunctive therapies significantly reduced the IOP at each time point and for the mean 24 h curve, except at 18:00 and 02:00 with DTFC and 02:00 with LTFC. When the three treatments were compared directly, the DTFC and latanoprost therapy demonstrated lower IOPs versus the other treatment groups, including: the mean 24 h pressure, maximum as well as minimum levels and individual time points following a modified Bonferroni correction (p<0.0032). CONCLUSIONS: This study showed DTFC, LTFC and the addition of DTFC to latanoprost significantly decrease the IOP compared with latanoprost alone, but the latter therapy regime yields the greatest IOP reduction. SN - 1468-2079 UR - https://www.unboundmedicine.com/medline/citation/18703549/Second_line_therapy_with_dorzolamide/timolol_or_latanoprost/timolol_fixed_combination_versus_adding_dorzolamide/timolol_fixed_combination_to_latanoprost_monotherapy_ L2 - https://bjo.bmj.com/lookup/pmidlookup?view=long&amp;pmid=18703549 DB - PRIME DP - Unbound Medicine ER -